RTI Health Solutions, Research Triangle Park, NC, U.S.A.
Duke Clinical Research Institute, Duke University, Durham, NC, U.S.A.
Br J Dermatol. 2017 Mar;176(3):777-785. doi: 10.1111/bjd.14798. Epub 2016 Sep 24.
Plaque psoriasis can have a significant negative effect on patients' quality of life, and treatments can result in serious toxicities. Although there have been several studies of patients' and physicians' relative preferences for the benefits and risks of psoriasis treatments, it is unclear how and whether patients' and physicians' preferences for the outcomes of psoriasis treatments differ.
To quantify patient and dermatologist preferences for improvements in psoriasis symptoms and for increases in the risk of treatment-related serious adverse events.
Members of the U.K. Psoriasis Association and U.K. dermatologists with experience prescribing biologics completed a web-enabled discrete-choice experiment survey in which they evaluated efficacy and safety features of biological treatments for psoriasis. Choices between hypothetical treatment options were used to estimate preference weights indicating respondents' relative trade-off preferences among treatment outcomes. These outcomes included improvements in the severity and coverage of psoriatic plaques and treatment-related risks of tuberculosis, serious infections and lymphoma. Preference estimates were used to derive the maximum level of side-effect risks that respondents would accept for improvements in psoriasis symptoms.
Respondents' tolerance for side-effect risks varied with side-effect severity and location of plaques, and risk tolerance for serious side-effects was greater for patients than for dermatologists.
Estimates of patients' risk tolerance for serious side-effects indicate that patients valued psoriasis symptom control highly and suggest that psoriasis symptoms have a significant effect on patients' quality of life. In light of research showing increased treatment satisfaction and improved treatment adherence among patients who receive therapies that are consistent with their preferences, our findings suggest that greater communication between dermatologists and patients about risk tolerance could help improve patient care.
斑块状银屑病会对患者的生活质量产生重大负面影响,而治疗可能会导致严重的毒性。尽管已经有几项关于患者和医生对银屑病治疗的益处和风险的相对偏好的研究,但尚不清楚患者和医生对银屑病治疗结果的偏好是否存在差异,以及如何存在差异。
量化患者和皮肤科医生对改善银屑病症状和增加与治疗相关的严重不良事件风险的偏好。
英国银屑病协会的成员和有经验开生物制剂处方的英国皮肤科医生完成了一项基于网络的离散选择实验调查,他们在该调查中评估了生物疗法治疗银屑病的疗效和安全性特征。在假设的治疗选择之间进行选择,以估计偏好权重,该权重表示受访者对治疗结果的相对权衡偏好。这些结果包括改善银屑病斑块的严重程度和覆盖范围以及与治疗相关的结核病、严重感染和淋巴瘤风险。使用偏好估计值来得出受访者愿意接受的最大副作用风险水平,以改善银屑病症状。
受访者对副作用风险的容忍度因副作用的严重程度和斑块的位置而异,并且患者对严重副作用的风险容忍度高于皮肤科医生。
对患者严重副作用风险的容忍度的估计表明,患者非常重视银屑病症状的控制,并表明银屑病症状对患者的生活质量有重大影响。鉴于研究表明,对与自身偏好一致的治疗方法有更高治疗满意度和更好的治疗依从性的患者,我们的研究结果表明,皮肤科医生和患者之间加强关于风险容忍度的沟通可以帮助改善患者的护理。